Business Wire

NILIT

26.8.2024 21:03:49 CEST | Business Wire | Press release

Share
Samsara Eco and NILIT Team up to Build World-First Nylon 6,6 Recycling Facility

Samsara Eco, the enviro-tech innovator and NILIT, the world’s leader in the production of nylon 6,6 for apparel, have announced plans to explore investment and construction of a nylon 6,6 textile-to-textile recycled polymer production site in South East Asia to help close the loop on nylon 6,6.

Roughly 4 million tonnes of nylon 6,6 is created every year, it is one of the most widely used fibers in the performance apparel and fashion industries. However, it is notoriously difficult to recycle and when blended with other fibres like spandex, it increases the challenge. Together, Samsara Eco and NILIT are seeking to address this issue head-on.

Aiming to be operational by late 2026, the anticipated facility will be uniquely capable of recycling textile waste, producing high-quality recycled nylon 6,6 polymers, for textile brands and manufacturers to seamlessly use in their existing supply chains to create new textile fabrics, infinitely.

“Our vision is to deliver climate repair through infinite recycling. One of the ways we’re achieving this is by creating the first circular pathway for nylon 6,6. Discarded clothing made from nylon 6,6 such as activewear, and even products like car interiors, typically end up in landfill or are incinerated at the end of life, which has dire consequences for our planet,” said Paul Riley, CEO and Founder of Samsara Eco.

Sarah Cook, Chief Commercial and Operations Officer of Samsara Eco also commented on the agreement: “By working with NILIT, we can reverse this trend and give apparel a new life. The MoU agreement is an important step to help brands and the world advance nylon 6,6 circularity and reduce plastic waste. We’re proud to be exploring a pilot recycling facility with NILIT, setting a precedent of what’s possible for future partners globally.”

“NILIT’s partnership with Samsara Eco is a critical step in our multi-pronged strategy to provide the apparel market with premium nylon 6,6 products that have lower environmental impact,” explained Ilan Melamed, NILIT General Manager. “Implementing textile-to-textile recycling solutions will substantially decrease global carbon emissions and reduce the 92 million tonnes of textile waste added to landfills annually. Together, NILIT and Samsara Eco have the potential to produce infinitely recycled nylon 6,6 that delivers outstanding fabric quality and performance while benefitting the planet.”

EosEco™ is the world's first technology to infinitely recycle nylon 6,6 by combining biophysics, chemistry, biology and computer science (such as AI) to create a family of plastic-eating enzymes. The enzymes break down plastic waste, including textiles made from nylon 6,6 into raw materials, which are then seamlessly integrated into existing manufacturing processes to create a truly closed loop. EosEco™ can recycle a breadth of feedstock inputs, including coloured and blended textiles like nylon 6,6 with spandex. EosEco™, together with NILIT’s unique polymerization, spinning and technology will be able to create premium recycled Nylon 6, 6 yarn for global consumption.

About NILIT

Celebrating 50 years of excellence, NILIT offers the broadest collection of premium sustainable Nylon 6,6 yarns designed to empower the apparel industry’s shift to a more sustainable position. Operating internationally, NILIT is the global leader in Nylon 6,6 yarns for apparel, dedicated to creating innovative and sustainable solutions that advance the textile industry.

NILIT will add Samsara Eco’s EosEco™ produced yarn to its innovative SENSIL® preferred portfolio of products which is manufactured according to NILIT’s Total Product Sustainability criteria. These responsible yarns give designers the beautiful, environmentally considerate performance fabrics they need to create apparel collections that respond to consumer demands.

About Samsara Eco

Samsara Eco is using advanced, enzymatic recycling to end plastic pollution. With breakthrough science, Samsara Eco has developed a new way to break plastic down to its core molecules, which can then be used to recreate brand-new plastic, again and again. Its patented technology, EosEco™ is a first-of-its-kind process that is genuinely better for the planet.

Samsara Eco’s community is united by the shared mission to divert plastic from our landfills and oceans, and eliminate the need to create plastic from fossil fuels, (whether it’s for the bottles we drink from or the clothes we wear) for a cleaner and more sustainable future.

In partnership with the Australian National University (ANU), Samsara Eco launched in 2020 with the backing of Main Sequence and Woolworths Group’s W23. It has raised more than AUD $160M in funding from local and global investors including Breakthrough Victoria, DCVC, Hitachi, lululemon, Temasek, Wildcard Ventures, Wollemi Capital and more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820332060/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye